German biotechnology company BioNTech estimated on Monday to be able to produce "
2 billion doses
" of the Covid-19 vaccine by the end of 2021, significantly more than the previous target of 1.3 billion doses.
To read also: "Vu d'Ailleurs" N ° 34 - The vaccine, new "liquid gold"
The German SME, associated with the American giant Pfizer, arrived at this new estimate taking into account the "
new standard
" allowing the administration of 6 doses per vial instead of 5, according to a document posted on its website. BioNTech is also counting on "
the expansion of its current facilities
", including the commissioning, expected in February, of another European production site in Marburg, Germany.
